FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Court Nixes Restraining Order Request in Entresto Suit

The Washington DC District Court rejects a Novartis motion in a generic drug carve-out case for a preliminary injunction to stay FDAs approval of MSN ...

latest-news-card-1
Federal Register

Class 2 for Nucleic Acid Covid Tests

Federal Register notice: FDA classifies into Class 2 devices that are intended to detect and identify nucleic acid targets in respiratory specimens fr...

latest-news-card-1
Marketing

FDA Pushed to Regulate Online Drug Promos

Gardner Law says prescription drug manufacturers and marketers need to be sure their social media promotions can withstand FDA scrutiny pushed by Cong...

latest-news-card-1
Federal Register

No-Longer-Marketed Enteregs Approval Withdrawn

Federal Register notice: FDA withdraws approval of Cubist Pharmaceuticals Entereg (alvimopan) capsules because it is no longer marketed.

latest-news-card-1
Federal Register

Regulatory Review Period for B+Ls Miebo

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Bausch + Lombs eye drug Miebo (perfluorohexyloc...

latest-news-card-1
Federal Register

FDA Debars Ryan Stabile for 15 Years

Federal Register notice: FDA debars Ryan Stabile for 15 years from importing or offering for import any drug into the U.S.

latest-news-card-1

More FDA Stringency Seen on Accelerated Drug OKs

Two Sheppard Mullin attorneys say sponsors of drugs approved through expedited pathways should learn from a recent FDA untitled letter faulting Mirais...

Medical Devices

FDA Clears Cresilons Traumagel

FDA clears Cresilons Traumagel device that uses a plant-based technology to control moderate to severe bleeding at the point of care.

latest-news-card-1
Human Drugs

FDA Touts CDER Advanced Manufacturing Research Facility

FDA describes CDERs new state-of-the-art advanced manufacturing research facility.

latest-news-card-1
Biologics

Priority Review for Imfinzi sBLA in Lung Cancer

FDA accepts for priority review an AstraZeneca supplemental BLA for Imfinzi (durvalumab) and its use in certain patients with limited-stage small cell...